Adrenoleukodystrophy National Registry Study

Adrenoleukodystrophy Clinical Trial

Official title:

Adrenoleukodystrophy National Registry Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03789721
• Other study ID #: 2019NTLS027
• Secondary ID: MT2019-01
• Status: Recruiting
• Start date: May 1, 2019
• Est. completion date: February 2030

Study information

• Verified date: May 2024
• Source: Masonic Cancer Center, University of Minnesota
• Contact: Ashish Gupta, MD
• Phone: 612-626-2961
• Email: gupta461[@]umn.edu
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The aim of this registry to understand the natural history and disease progression in ALD and potentially develop bio-markers using the biospecimens collected using this registry.

Description:

This is a prospective, non-therapeutic protocol designed to create and maintain a registry of participants with Adrenoleukodystrophy (ALD) and known/presumed mutation for ALD. This study also involves maintaining a prospective biorepository to collect and store buccal swab, blood, stool and urine samples as well. In this protocol, pediatric (including infants), adolescents and adult patients with confirmed or presumed ALD (based on positive VLCFA testing and/or confirmed mutation) will be offered potential study participation. Additionally, presumed mutation for ALD (based on pedigree or confirmed mutation) will be offered potential study participation. After appropriate consent (online or in-person), subjects will be requested to provide a medical history (with authorization of release of medical records), longitudinal biospecimens, and permission to perform laboratory analyses on these samples. The overall goal is to understand the natural disease course in affected and unaffected patients (identified patients and relatives with a diagnosis of ALD), as well as women with ALD to assemble a resource of clinical, medical, and biological data from the participants. This study also aims to understand the outcomes of this disease, as well as possibly develop biomarkers to identify prognostic markers for disease progression, which may help develop effective interventions. The biospecimen bank and registry will provide access to samples and data for the ongoing studies as well as will provide an important resource for the future research.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: February 2030
• Est. primary completion date: February 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria

• Age 0 - 100

• ALD patients or family member meeting any of the following criteria:

• Any patient diagnosed with ALD (confirmed by positive VLCFA testing and/or genetic mutation).

• Known or presumed mutation with ALD based on pedigree or confirmed mutation in ABCD1 gene

• Participants living in the United States and territories

Exclusion Criteria

• Patients diagnosed with ALD who lack the capacity to consent/assent AND do not have a designated legally authorized representative or guardian.

• Patients who have undergone BMT or other cellular therapy .

• Patients not fluent in English who are unable to consent in-person at the BMT Journey Clinic.

• Patients who are illiterate

• Patient determined by the PI or designee to be unlikely to complete required study components (due to language barriers, compliance issues, etc.)

Related Conditions & MeSH terms

• Adrenoleukodystrophy
• ALD (Adrenoleukodystrophy)
• Cerebral Adrenoleukodystrophy

Intervention

Other:
• Medical Record Abstraction
Collect clinical and epidemiological data through medical record abstraction and self-reported questionnaire survey semi-annually.
• Biospecimen Sample Collection
Collect research samples, when feasible for those diagnosed with ALD.

Locations

Country	Name	City	State
United States	Masonic Cancer Center at University of Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Collect Clinical and Epidemiological Data	Collect clinical and epidemiological data through medical record abstraction and self-reported questionnaire survey semi-annually.	10 Years